Takeda Pharmaceutical Company Limited announced the exercise of its option to acquire Maverick Therapeutics, Inc. a private biopharmaceutical company pioneering conditionally active bispecific T-cell targeted immunotherapies.
The 48-week results from the Phase III MODERN study comparing Celsentri/Selzentry (maraviroc), from ViiV Healthcare, dosed once daily with darunavir/ritonavir...
Background: Patients with untreated obstructive sleep apnoea (OSA) have increased motor vehicle collisions (MVCs). When successfully treated, they report improved driving and fewer mishaps, but there are few objective data to confirm this.